Of note, semaglutide is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis, as stated in the SmPC
Theyre likely to be taking these drugs for shorter durations, so any consumer-facing company thats adjusting product and marketing strategies in response to the rise in usage rates were seeing for these drugs should also be taking into account that a larger underlying user base means that we'll be seeing a growing number of consumers who are also stopping and ceasing these drugs over time as well. How To Respond In addressing how retailers and food and beverage companies should respond, Circana said that while some consumers will resume their pre-GLP-1 purchase habits when they cease treatment, for many others, varying forms of the medication, supplements and CPG food and beverage will play critical roles in how individuals manage their conditions. Some areas of opportunity include: Product innovation: Develop and promote products that align with the dietary needs of GLP-1 users, Circana said
Patients can use the platform to communicate with their care team regarding treatment progress, medication questions, side effects and refill requests
Clarify any aspects of GLP-1 therapy that you don't understand, and inquire about how it compares to other treatment options available to you
